Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

What the Experts Are Talking About: Advances in Immune Checkpoint Inhibition for NSCLC Therapy

In 2017, it is estimated that there will be approximately 222,500 newly diagnosed cases of lung cancer and 155,870 associated lung cancer deaths. T...

Available credits: 0.75


Valid until:

  • Overview

    In 2017, it is estimated that there will be approximately 222,500 newly diagnosed cases of lung cancer and 155,870 associated lung cancer deaths. The majority of lung cancer diagnoses, approximately 85%, are those of non-small cell lung cancer (NSCLC), which are associated with poor patient outcomes. The recent clinical evaluation and FDA approval of several immune checkpoint inhibitors for the treatment of NSCLC have provided significant response rates and enhanced survival compared to current chemotherapy approaches. However, questions pertaining to biomarkers for patient selection, management of adverse events, and integration of immune checkpoint inhibitors into clinical practice remain challenging.

    Therefore, within this CME activity, experts in the field discuss effective treatment strategies for the care of patients with NSCLC that take into consideration biomarkers, the most recent clinical evidence regarding the use of immune checkpoint inhibitors, as well as identification and management of immune-related adverse events.

  • Learning Objectives

    Upon successful completion of this educational activity, participants should be better able to:

    • Implement effective treatment strategies for patients with NSCLC based on knowledge of patient biomarkers and the most recent clinical evidence regarding the use of immune checkpoint inhibitors.
    • Monitor patients undergoing immune checkpoint inhibitor-based therapy for immune-related adverse events and adjust the care plan accordingly.
  • Target Audience

    The intended audience for the activity is medical oncologists, pathologists, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

    Faculty members report the following relationship(s):

    Naiyer A. Rizvi, MD
    Consulting Fee: AstraZeneca, Merck, Novartis, Roche
    Ownership Interest: Gritstone Oncology

    Leora Horn, MD
    Consulting Fee: AbbVie, Genentech, Lilly, Merck
    Contracted Research: Ariad, Astellas, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Janssen, Lilly, Xcovery
    Consulting (unpaid): Bristol-Myers Squibb, Xcovery

    Reviewer reports the following relationship(s):
    Fred R. Hirsch, MD, PhD
    Consulting Fee: AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, HTG, Lilly, Merck, Ventana

    Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
    No relevant financial relationships to disclose.

    Vindico Medical Education staff report the following relationship(s):
    No relevant financial relationships to disclose.

    Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

  • Accreditation and Credit Designation Statements

    This continuing medical education activity is provided by 

    Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

  • Terms of Use

    How to Participate in this Activity and Obtain CME Credit:
    To participate in this CME activity, you must read the objectives, answer the pretest question, view content, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


  • Disclaimer

    Unlabeled and Investigational Usage:
    The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

    Copyright Statement:
    Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    CME Questions?
    Contact us at


  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.